Us6303146b1 - Solid Oral Dosage Form Comprising A Combination Of Metformin And Glibenclamide - Google Patents
US6303146B1 - Solid oral dosage form comprising a combination of metformin and glibenclamide - Google Patents Solid oral dosage form comprising a combination of metformin and glibenclamide US6303146B1 US09353141 US35314199A US6303146B1 US 6303146 B1 US6303146 B1 US 6303146B1 US 09353141 US09353141 US 09353141 US 35314199 A US35314199 A US 35314199A US 6303146 B1 US6303146 B1 US 6303146B1 Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) A61MEDICAL OR VETERINARY SCIENCE; HYGIENE A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES A61K31/00Medicinal preparations containing organic active ingredients A61K31/155Amidines (), e.g. guanidine (H2NC(=NH)NH2), isourea (N=C(OH)NH2), isothiourea (N=C(SH)NH2) A61MEDICAL OR VETERINARY SCIENCE; HYGIENE A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES A61K31/00Medicinal preparations containing organic active ingredients A61K31/64Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide The present invention relates to a solid oral dosage form comprising a combination of metformin and glibenclamide in which the size of glibenclamide is such that the glibenclamide bioavailability is comparable to the glibenclamide bioavailability obtained with a separate administration of metformin and glibenclamide. The present invention r
- Glibenclamide and metfoRmin versus stAndard care in gEstational diabeteS (GRACES): a feasibility open label randomised trial
- Growth in diabetes products lags, but Medtronic earnings solid
- The Powerful Combination Of Garlic, Apple Cider Vinegar And Honey Can Fight Diabetes, Obesity, Indigestion And Many More!
Glibenclamide And Metformin - Drug Information
General Information on Glibenclamide and Metformin Generic Name :Glibenclamide and Metformin Pronunciation :GLY-BEN-CLA-AMIDE +MetFORE-min Latest prescription information about Glibenclamide and Metformin. Learn how to pronounce the drug's name, its indications, dosage, how to take, when to take, when not to take, side effects, special precautions, its storage instructions and warnings if any when taken during pregnancy. Also listed are the International and Indian trade name(s) of the drug and its price list. ICD Code : Y42.3 | Therapeutic Classification : Antidiabetics Trade Names/Brand Names of Glibenclamide and Metformin India- Aviglen Fo, Aviglen-Mf, Benclamet, Benformin, Ben-Q-Met, Clamet, Clamet-C, Mide Plu, Combidos, Cuben-M, Daocon-M, Daonil-M, Diabetrol, Diatrac-M, Diolin-M, Dior Plus, Duotrol-Sr, Eumet-D, G-Formin, G-Formin-F, G-Formin-P, Glibact-M, Glibomet, Glibomet F, Glifil M F, Glinil-M, Glitrac-M, Glucomin-P, Gluconil-M, Glucored, Glucored F, Glucotrac, Glutowin F, Glycurb, Iscept. Iscept For, Iscpet 500, Iscept-L, Iscept-P, Melitus, Metclam, Metclam Fo, Metica G, Sugatrol, Sugatrol F, Sugnl-M, Triglycome. Why is Glibenclamide and Metformin Prescribed? (Indications) This medication contains sulfonylurea and biguanide antidiabetic combination, prescribed for type 2 diabetes. When should Glibenclamide and Metformin not to be taken? (Contraindications) Contraindicated in patients with severe kidney disease, chronic metabolic acidosis, diabetic ketoacidosis, with or without coma, and hypersensitivity. What is the dosage of Glibenclamide and Metformin? Adult: PO- Per tab contains glibenclamide 1.25 mg and metformin 250 mg. As initial therapy: Start with 1 tab 1-2 times/day. It may be increased if needed. How should Glibenclamide and Metformin be taken? It c Continue reading >>
Glucovance, (glyburide-metformin) Dosing, Indications, Interactions, Adverse Effects, And More
1.25/250 mg glyburide/metformin PO qDay or q12hr May titrate up at 2 week intervals; maximum 20/2000 mg/day Hepatic impairment: Avoid use; cases of lactic acidosis reported eGFR 30-45 mL/min/1.73 m: Not recommended to initiate treatment Monitor eGFR at least annually or more often for those at risk for renal impairment (eg, elderly) If eGFR falls below 45mL/min/1.73 m while taking metformin, risks and benefits of continuing therapy should be evaluated If eGFR falls below 30 mL/min/1.73 m: while taking metformin, discontinue the drug 1.25/250 mg glyburide/metformin PO qDay or q12hr Adjust conservatively in patients with advanced age; do not use in patients >80 years unless renal function is assessed (do not titrate to maximum dose) Gastrointestinal: Cholestatic jaundice and hepatitis may occur rarely which may progress to liver failure; discontinue drug Allergic: Angioedema, arthralgia, myalgia, and vasculitis Dermatologic: Porphyria cutanea tarda and photosensitivity Hematologic: Leukopenia, agranulocytosis, thrombocytopenia, which occasionally may present as purpura, hemolytic anemia, aplastic anemia, and pancytopenia Metabolic: Hepatic porphyria reactions reported with sulfonylureas but not with glyburide; disulfiram-like reactions reported very rarely with glyburide; cases of hyponatremia reported most often in patients who are on other medications or have medical conditions known to cause hyponatremia or increase release of antidiuretic hormone Liver function abnormalities, including isolated transaminase elevations (glyburide) Discontinue metformin at the time of or before an iodinated contrast imaging procedure in patients with an eGFR between 30-60 mL/minute/1.73 m; in patients with a history of liver disease, alcoholism, or heart failure; or in patients who wil Continue reading >>
Combination Of Glibenclamide-metformin Hcl For The Treatment Of Type 2 Diabetesmellitus.
1. Expert Opin Pharmacother. 2012 Dec;13(17):2545-54. doi:10.1517/14656566.2012.738196. Epub 2012 Nov 2. Combination of glibenclamide-metformin HCl for the treatment of type 2 diabetesmellitus. (1)University of Maryland Medical Center, Endocrinology, Diabetes and Metabolism, Baltimore, Maryland 21201, USA. INTRODUCTION: Combination of glibenclamide (glyburide in the U.S.) and metformin hydrochloride simultaneously addresses two different but complimentary mechanismsto improve glycemic control in type 2 diabetes.AREAS COVERED: The pharmacokinetics, efficacy, and side effect profile of theoral combination of glibenclamide-metformin are reviewed.EXPERT OPINION: Those patients, uncontrolled with single oral agent sulfonylurea or metformin alone, benefit from combination glibenclamide-metformin. There isimprovement in fasting plasma glucose, HbA(1C), and post-prandial glucosecontrol, and patients are more likely to achieve a HbA(1C) < 7%. Initiationshould be started at the lowest doses and titrated to get the desired effect.Combination therapy allows for reduced pill burden while treating amultifactorial disease by two different mechanisms. Practitioners should becognizant of risks of hypoglycemia and the theoretical potential for lacticacidosis in the elderly and those with renal impairment. We caution the use ofglibenclamide-metformin in patients at risk for cardiovascular disease. Therapyshould be individualized, but overall, combination of glibenclamide-metforminshould be considered in patients, without renal or cardiovascular impairment, whoare not controlled on monotherapy alone. Alternatively, practitioners may want toweigh the efficacy and safety of available dipeptidyl-peptidase-4inhibitor-metformin combinations to those of glibenclamide-metformin whenconsidering c Continue reading >>
- Type 2 Diabetes: Mastering Injectable Combination Therapies to Individualize & Optimize Outcomes
- Lilly's Trulicity (dulaglutide) Label Updated to Include Use in Combination with Basal Insulin for Adults with Type 2 Diabetes
- Relative effectiveness of insulin pump treatment over multiple daily injections and structured education during flexible intensive insulin treatment for type 1 diabetes: cluster randomised trial (REPOSE)
Glibenclamide, Metformin, And Insulin For The Treatment Of Gestational Diabetes: A Systematic Review And Meta-analysis
Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis BMJ 2015; 350 doi: (Published 21 January 2015) Cite this as: BMJ 2015;350:h102 Montserrat Balsells, registrar in endocrinology and nutrition 1 , Apolonia Garca-Patterson, registrar in endocrinology and nutrition 2 , Ignasi Gich, associate researcher 5 6 7 , Rosa Corcoy, assistant professor in endocrinology and nutrition 2 8 9 1Department of Endocrinology and Nutrition, Hospital Universitari Mtua de Terrassa, Terrassa 8821, Spain 2Department of Endocrinology and Nutrition, Hospital de la Santa Creu i Sant Pau, Barcelona 08025, Spain 3Iberoamerican Cochrane Centre, Hospital de la Santa Creu i Sant Pau, Barcelona 4Institute of Biomedical Research (IIB Sant Pau), Hospital de la Santa Creu i Sant Pau Barcelona 5CIBER Epidemiologa y Salud Pblica (CIBERESP), Instituto de Salud Carlos III, Madrid 28029, Spain 6Department of Epidemiology, Hospital de la Santa Creu i Sant Pau, Barcelona 7Department of Clinical Pharmacology and Therapeutics, Universitat Autnoma de Barcelona, Bellaterra 08193 (Cerdanyola del Valls), Spain 8CIBER Bioengineering, Biomaterials and Nanotechnology (CIBER-BBN), Instituto de Salud Carlos III, Madrid 9Department of Medicine, Universitat Autnoma de Barcelona, Bellaterra Correspondence to: R Corcoy, Servei dEndocrinologia i Nutrici, Hospital de la Santa Creu i Sant Pau, Avinguda Sant Antoni Maria Claret 167, Barcelona 08025, Spain rcorcoy{at}santpau.cat Objective To summarize short term outcomes in randomized controlled trials comparing glibenclamide or metformin versus insulin or versus each other in women with gestational Continue reading >>
- Glibenclamide and metfoRmin versus stAndard care in gEstational diabeteS (GRACES): a feasibility open label randomised trial
- Quality of Life in Women with Gestational Diabetes Mellitus: A Systematic Review
- Glycaemic control in people with type 2 diabetes mellitus during and after cancer treatment: A systematic review and meta-analysis
The Development Of An Oral Antidiabetic Combination Tablet: Design, Evaluation And Clinical Benefits For Patients With Type 2 Diabetes
The Challenge of Designing an Antidiabetic Combination Tablet The combination of an insulin sensitiser, e.g. metformin, and an insulin secretagogue, e.g. glibenclamide, represents a rational choice of agents for inclusion within a combination tablet, as they address the underlying endocrine disturbances present in patients with type 2 diabetes. In addition, the pharmacokinetics of metformin and glibenclamide both support twice-daily dosing. Furthermore, the co-administration of metformin and glibenclamide is proven to effectively control glycaemia in patients with type 2 diabetes.[ 7 , 8 ] Indeed, metformin and glibenclamide probably represent the most widely used free combination of oral antidiabetic agents worldwide. Metformin is still the only oral antidiabetic agent proven to reduce the total burden of microvascular and macrovascular diabetic complications and to prolong the lives of type 2 diabetic patients. The landmark UK Prospective Diabetes Study (UKPDS) evaluated the effects of metformin on glycaemic control and clinical outcomes in overweight type 2 diabetic patients with hyperglycaemia despite previous treatment with diet and exercise, over a median follow-up period of 10 years.[ 9 ] Compared with conventional, diet-based treatment, intensive glycaemic management with metformin was associated with significant reductions in the incidence of diabetes-related and all-cause mortality (p = 0.017 and p = 0.011, respectively), any diabetes-related endpoint (p = 0.002) and myocardial infarction (p = 0.01). Furthermore, metformin treatment is often associated with reductions in body weight in overweight patients, and with improvements in lipid profiles in dyslipidaemic patients.[ 10 , 11 ] Glibenclamide is the only sulphonylurea shown to reduce the risk of diabetic Continue reading >>
Glibenclamide + Metformin: Indication, Dosage, Side Effect, Precaution | Cims India
Adult: Each tab contains glibenclamide (mg)/metformin (mg): 1.25/250, 2.5/500, 5/500: Patients inadequately controlled on diet and exercise: Initially, 1.25 mg/250 mg 1-2 times daily. Patients w/ HbA1c >9% or fasting plasma glucose (FPG) >200 mg/dL: Initially, 1.25 mg/250 mg bid. May adjust daily dose in increments of 1.25 mg/250 mg at intervals of not less than 2 wk. Max: Glibenclamide 10 mg and metformin 2,000 mg daily. Patients inadequately controlled on sulfonylurea and/or metformin: Initially, 2.5 mg/500 mg or 5 mg/500 mg bid. May adjust daily dose in increments not more than 5 mg/500 mg. Max: Glibenclamide 20 mg and metformin 2,000 mg daily. Symptoms: Mild to severe hypoglycaemia which may lead to hypoglycaemic coma (glibenclamide); lactic acidosis (metformin). Management: Mild hypoglycaemia w/o loss of consciousness may be treated w/ oral glucose. Severe hypoglycaemic reactions w/ coma, seizure or other neurological impairment require immediate hospitalisation. Admin rapid IV inj of glucose 50% soln in case of hypoglycaemic coma. Haemodialysis may be useful for removal of accumulated drugs in metformin overdose. Diabetic ketoacidosis or diabetic pre-coma; acute conditions which may alter renal function (e.g. dehydration, severe infection, shock); acute or chronic disease which may cause tissue hypoxia (e.g. cardiac or resp failure, recent MI, acute significant blood loss, sepsis, gangrene); major surgery, porphyria. Acute alcohol intoxication/alcoholism. Renal (CrCl <60 mL/min) or hepatic impairment. Lactation. Concomitant use w/ bosentan, miconazole and intravascular admin of iodinated contrast materials. Patient w/ impaired adrenal and/or pituitary function, G6PD deficiency, heart failure. Pregnancy. Patient Counselling May impair ability to drive or operate m Continue reading >>
Glyburide And Metformin (oral Route)
Follow carefully the special meal plan your doctor gave you. This is the most important part of controlling your diabetes, and is necessary if the medicine is to work properly. Also, exercise regularly and test for sugar in your blood or urine as directed. This medicine comes with a patient information insert. Read and follow the instructions carefully. Ask your doctor if you have any questions. Glyburide and metformin combination should be taken with meals to help reduce the stomach adverse effects that may occur during the first few weeks of treatment. The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so. The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine. AdultsAt first, 1.25 milligrams (mg) of glyburide and 250 mg of metformin one or two times a day with meals. Your doctor may increase your dose a little at a time every two weeks until your blood sugar is controlled. However, the dose is usually not more than 20 mg of glyburide and 2000 mg of metformin per day. ChildrenUse and dose must be determined by your doctor. For patients previously treated with a sulfonylurea antidiabetic agent and/or metformin: AdultsAt first, 2.5 milligrams (mg) of glyburide and 500 mg of metformin or 5 mg of glyburide and 500 mg of metformin two times a day, with the morning and evening meals. Your doctor may increase your dose a little at a time Continue reading >>
Efficacy Of Adding Glutazone To The Maximum Dose Of Glibenclamide And Metformin Resistant On Type 2 Diabetic Patients - Caspian Journal Of Internal Medicine
Efficacy of adding glutazone to the maximum dose of glibenclamide and metformin resistant on type 2 diabetic patients Naser Aghamohammadzadeh , Ali Tabrizi , Mitra Niafar , Farzad Najafipor Background: To evaluate the efficacy of adding the glutazone to maximum dose of sulfonylurea and metformin in patients with poorly controlled type 2 diabetes. Methods: Ninety six patients with type 2 diabetes who had failed medical therapy with maximal-dosage of metformin and glibenclamide received glutazone. Fasting blood sugar (FBS), 2 hours postprandial (2hpp) glucose, hemoglobin A1C, cholesterol and HDL levels were assessed at baseline three months later. Results: Ninety-six patients with type 2 diabetes (74 women and 22 men) with the mean age of 55.79.9 years were studied. Significant reduction was seen in fasting blood sugar (FBS), 2 hours postprandial (2hpp) glucose, hemoglobin A1C and triglyceride levels three months after adding glutazone to therapeutic regimen (p<0.0005). There was not a significant rise in cholesterol and HDL levels before and after the new therapy. Conclusion: The results show that the combination of glutazone, metformin and glibenclamide may result in better control of glycemic status in diabetic patients resistant to oral first-line agents. Continue reading >>
- Glibenclamide and metfoRmin versus stAndard care in gEstational diabeteS (GRACES): a feasibility open label randomised trial
- Caffeinated and Decaffeinated Coffee Consumption and Risk of Type 2 Diabetes: A Systematic Review and a Dose-Response Meta-analysis
- Mobile App-Based Interventions to Support Diabetes Self-Management: A Systematic Review of Randomized Controlled Trials to Identify Functions Associated with Glycemic Efficacy
Glyburide / Metformin Dosage
-As Initial Therapy in Patients with Inadequate Glycemic Control on Diet and Exercise Alone: Starting dose: 1.25 mg-250 mg orally once a day -Consider a starting dose of 1.25 mg-250 mg orally twice a day for patients with fasting blood glucose (FBG) greater than 200 mg/dL or HbA1c greater than 9% Maintenance Dose: Increase in increments of 1.25 mg-250 mg per day every 2 weeks up to the minimum effective dose to achieve glycemic control Maximum Initial Dose: 10 mg-2000 mg per day -Patients with Inadequate Glycemic Control on a Glyburide (or another Sulfonylurea) and/or Metformin: Initial dose: 2.5 mg-500 mg or 5 mg-500 mg orally twice a day Maintenance Dose: Increase in increments of no more than 5 mg-500 mg to the minimum effective dose to achieve adequate blood glucose control Continue reading >>
Glibenclamide + Metformin: Indication, Dosage, Side Effect, Precaution | Cims India
For action to be taken in the event of accidental overdose ... click to view glibenclamide + metformin Diabetic ketoacidosis or diabetic pre-coma; acute conditions which may alter renal function (e.g. dehydration, severe infection, shock); acute or chronic disease which may cause tissue hypoxia (e.g. cardiac or resp failure, recent MI, acute significant blood loss, sepsis, gangrene); major surgery, porphyria. Acute alcohol intoxication/alcoholism. Renal (CrCl <60 mL/min) or hepatic impairment. Lactation. Concomitant use w/ bosentan, miconazole and intravascular admin of iodinated contrast materials. Patient w/ impaired adrenal and/or pituitary function, G6PD deficiency, heart failure. Pregnancy. Patient Counselling May impair ability to drive or operate machinery. Monitoring Parameters Monitor urine for glucose and ketones, FPG, HbA1c, and fructosamine; haematologic parameters, renal and hepatic function; vit B12 and folate levels (if anaemia is suspected); signs and symptoms of hypoglycaemia. Hypoglycaemia, haemolytic anaemia, wt gain, upper resp infection, diarrhoea, headache, nausea and vomiting, abdominal pain, dizziness. Decreased hypoglycaemic effect w/ thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, oestrogen, OC, phenytoin, nicotinic acid, sympathomimetics, Ca channel blockers, isoniazid. Glibenclamide: Increased hypoglycaemic effect w/ NSAIDs and other highly protein bound drugs, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, MAOIs, -blockers. Decreased plasma concentration w/ colesevelam. Metformin: Increased plasma concentration w/ furosemide, nifedipine and cimetidine. Potentially Fatal: Increased risk of hepatotoxicity w/ bosentan. Risk of severe hypoglycaemia w/ miconazole (systemic route, oromucosal g Continue reading >>
Metcon-g (metformin Hydrochloride & Glibenclamide) Barata Pharmaceuticals Limited
Type 2 diabetes mellitus not adequately controlled with either metformin or sulfonylurea monotherapy. MECHANISM OF ACTION: Metformin belongs to a group of medicines called biguanides. It lowers blood glucose by helping the body make better use of insulin. Glibenclamide belongs to the group of medicines called sulfonylureas. It lowers blood glucose by increasing the amount of insulin produced by the human pancreas. DOSAGE AND ADMINISTRATION: The dose varies from person to person. People who do not respond to either metformin or sulfonylurea medicine alone: The usual starting dose is one Metformin Hydrochloride and Glibenclamide Tablets 500mg/2.5mg tablet once a day Replacing combined use of metformin and a sulfonylurea or Glibenclamide. The usual starting dose is one to two tablets of Metformin Hydrochloride and Glibenclamide Tablets 500mg/2.5mg daily. Elderly people: the dose depends on the renal function. The usual starting dose for elderly patients may be one Metformin Hydrochloride and Glibenclamide tablets 250mg/1.25mg tablet daily. Smaller doses may be prescribed in cases of kidney problems or generally poor health. Increase the dose slowly over one or two weeks, depending on your blood glucose levels and other tests. The usual maximum recommended dose is one Metformin Hydrochloride and Glibenclamide Tablets 500mg/5mg tablet three times a day. Hypersensitivity to metformin hydrochloride or glibenclamide or to any of the excipients Acute conditions with the potential to alter renal function such as: dehydration, severe infection, shock & intravenous administration of iodinated contrast agents. Acute or chronic disease which may cause tissue hypoxia such as: cardiac or respiratory failure, recent myocardial infarction, shock. Hepatics insufficiency, acute alcohol in Continue reading >>
Glyburide-metformin, Oral Tablet
Glyburide/metformin oral tablet is available only as a generic drug. It’s not available in a brand-name version. Glyburide/metformin only comes as a tablet you take by mouth. Glyburide/metformin is used to treat type 2 diabetes. This drug has a black box warning. This is the most serious warning from the Food and Drug Administration (FDA). A black box warning alerts doctors and patients about drug effects that may be dangerous. Glyburide/metformin can cause lactic acidosis. Don’t use this drug if you already have lactic acidosis. Lactic acidosis is a rare problem that happens when oxygen levels in your body drop. This leads to a buildup of lactic acid in your bloodstream. The condition can sometimes be fatal. Your risk of lactic acidosis may be higher if you have diabetes with kidney damage or heart failure. Other warnings Surgery or medical procedures warning: If you’re going to have surgery, magnetic resonance imaging (MRI), computerized tomography (CT) scan, or any other procedure, your doctor may temporarily stop your treatment with glyburide/metformin. Having procedures done that use radiocontrast dyes while taking this drug can cause kidney failure or lactic acidosis. Sun sensitivity warning Glyburide/metformin can make your skin more sensitive to the sun. This means you’re more likely to get sunburned. While you’re taking this drug, use sunscreen and wear protective clothing whenever you’re in the sun. Don’t use sun lamps or tanning beds or booths. Low blood sugar (hypoglycemia) warning: Glyburide/metformin can cause severe low blood sugar (hypoglycemia). This can cause seizures or fainting. It’s important to know how to spot and treat low blood sugar reactions as directed by your doctor. Symptoms may include: shakiness nervousness or anxiety swea Continue reading >>
Glibenclamide - An Overview | Sciencedirect Topics
Glibenclamide (GBC) is an oral hypoglycemic drug that stimulates the pancreatic beta cells to secrete insulin and is often used to treat diabetes, including diabetes during pregnancy. Mark G. Papich DVM, MS, DACVCP, in Saunders Handbook of Veterinary Drugs (Fourth Edition) , 2016 Glyburide is a sulfonylurea oral hypoglycemic agent; it is also known as glibenclamide. This drug acts to increase secretion of insulin from the pancreas, probably by interacting with sulfonylurea receptors on beta cells or by interfering with ATP-sensitive potassium channels on pancreatic beta cells, which increases secretion of insulin. These drugs also may increase sensitivity of existing insulin receptors. It is used as oral treatment in the management of diabetes mellitus, particularly in cats. The response rate is approximately 40%. Sulfonylurea drugs include glipizide (Glucotrol) and glyburide (DiaBeta, Micronase). Metformin is of the biguanide class of oral drugs for diabetes. R.C.L. Page, in Side Effects of Drugs Annual , 2010 Glibenclamide is metabolized by the liver mainly by CYP2C9, but also by CYP2C19 and CYP3A4. Sitagliptin is excreted via the kidney mainly unchanged. CYP3A4 and CYP2C8 are involved to a limited extent in its metabolism. The effect of glibenclamide (glyburide) on the pharmacokinetics of sitagliptin has been investigated in an open study in eight people, aged 2244 years, who took glibenclamide 1.25mg alone and then again after having taken sitagliptin 200mg/day for 5 days (twice the usual prescribed dose); a further dose of sitagliptin was taken on day 6 (45c). The AUC of glibenclamide was 193 hours.ng/ml when taken with sitagliptin and 177 without; Cmax was 32 in both conditions. Thus, sitagliptin had little effect on the disposition of glibenclamide. Umamaheswara Continue reading >>
Glucovance
NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. What is in this leaflet It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have benefits and risks. Your doctor has weighed the risks of you taking Glucovance against the benefits expected for you. If you have any concerns about taking this medicine, talk to your doctor or pharmacist. What Glucovance is used for Glucovance is used to control blood glucose levels (the amount of sugar in the blood) in adults with type II diabetes mellitus. This type of diabetes is also known as non-insulin dependent diabetes mellitus (NIDDM) or maturity onset diabetes. when diet, exercise and treatment with either metformin or a sulfonylurea medicine are not enough to control your blood glucose in people whose blood sugar levels are already well controlled by the combination of metformin and a sulfonylurea medicine. Glucovance is to replace these two medicines. Glucovance contains two active ingredients, metformin hydrochloride and glibenclamide. Metformin belongs to a group of medicines called biguanides. Metformin lowers blood glucose by helping your body make better use of insulin. Glibenclamide belongs to a group of medicines called sulfonylureas. Glibenclamide lowers blood glucose by increasing the amount of insulin produced by your pancreas. If your blood glucose is not properly controlled, you may experience hypoglycaemia (low blood glucose) or hyperglycaemia (high blood glucose). If not treated quickly, these may progress to: Hyperglycaemia (high blood glucose) usually occurs more slowly than hypoglycaemia. Signs of hyperglycaemia may include: Long-term hyperglycaemia can lead to serious problems such as hea Continue reading >>
